ISIS-STAT3Rx: Phase Ib/IIa started

Isis said that partner AstraZeneca began an open-label, dose-escalation Phase Ib/IIa trial evaluating ISIS-STAT3Rx in about 61 patients with advanced or metastatic HCC who have failed first-line thera...